(BMI) Badger Meter - Ratings and Ratios
Meters, Valves, Sensors, Software
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.89% |
| Yield on Cost 5y | 1.48% |
| Yield CAGR 5y | 18.13% |
| Payout Consistency | 97.1% |
| Payout Ratio | 31.5% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 37.7% |
| Value at Risk 5%th | 57.3% |
| Relative Tail Risk | -7.63% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.46 |
| Alpha | -33.77 |
| CAGR/Max DD | 0.47 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.301 |
| Beta | 0.906 |
| Beta Downside | 0.658 |
| Drawdowns 3y | |
|---|---|
| Max DD | 34.12% |
| Mean DD | 9.92% |
| Median DD | 6.78% |
Description: BMI Badger Meter January 07, 2026
Badger Meter Inc. (NYSE:BMI) designs, manufactures, and markets flow-measurement and water-smart-metering solutions for municipal utilities, industrial users, and OEMs. Its product portfolio spans flow meters, valves, optical and electrochemical water-quality sensors, high-frequency pressure and leak-detection devices, and the BEACON cloud-based software suite that delivers alerts and consumer-engagement tools. Sales are executed both directly and through a network of distributors and OEM representatives, serving sectors such as water/wastewater, HVAC, and corporate sustainability.
Key recent metrics (FY 2023) include approximately $1.1 billion in revenue, a 5 % year-over-year growth rate, and an operating margin near 12 %. The company’s backlog of recurring smart-metering contracts exceeded $300 million, reflecting strong demand driven by U.S. water-infrastructure spending, which the American Water Works Association estimates will total roughly $1 trillion over the next decade. Additionally, ESG-focused capital allocation-particularly utilities’ need to meet tightening water-conservation regulations-continues to boost adoption of Badger’s advanced metering infrastructure.
For deeper quantitative analysis, you might explore ValueRay’s platform for detailed financial metrics and peer comparisons.
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (138.8m TTM) > 0 and > 6% of Revenue (6% = 54.1m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 0.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 37.86% (prev 49.78%; Δ -11.92pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.18 (>3.0%) and CFO 181.0m > Net Income 138.8m (YES >=105%, WARN >=100%) |
| Net Debt (-201.7m) to EBITDA (207.7m) ratio: -0.97 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.22 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (29.6m) change vs 12m ago 0.12% (target <= -2.0% for YES) |
| Gross Margin 41.26% (prev 39.55%; Δ 1.72pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 101.2% (prev 100.1%; Δ 1.07pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -3.28 (EBITDA TTM 207.7m / Interest Expense TTM -43.5m) >= 6 (WARN >= 3) |
Altman Z'' 7.98
| (A) 0.35 = (Total Current Assets 494.6m - Total Current Liabilities 153.4m) / Total Assets 978.3m |
| (B) 0.64 = Retained Earnings (Balance) 624.1m / Total Assets 978.3m |
| (C) 0.16 = EBIT TTM 142.7m / Avg Total Assets 890.6m |
| (D) 2.42 = Book Value of Equity 666.4m / Total Liabilities 275.8m |
| Total Rating: 7.98 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 81.30
| 1. Piotroski 6.0pt |
| 2. FCF Yield 3.31% |
| 3. FCF Margin 18.45% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -0.97 |
| 6. ROIC - WACC (= 6.71)% |
| 7. RoE 21.12% |
| 8. Rev. Trend 97.93% |
| 9. EPS Trend 30.74% |
What is the price of BMI shares?
Over the past week, the price has changed by -1.30%, over one month by -1.85%, over three months by -2.63% and over the past year by -18.24%.
Is BMI a buy, sell or hold?
- Strong Buy: 2
- Buy: 2
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BMI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 219 | 25.8% |
| Analysts Target Price | 219 | 25.8% |
| ValueRay Target Price | 181.3 | 4.1% |
BMI Fundamental Data Overview January 07, 2026
P/E Trailing = 37.7463
P/E Forward = 33.3333
P/S = 5.7894
P/B = 7.3994
P/EG = 3.3377
Beta = 0.906
Revenue TTM = 901.1m USD
EBIT TTM = 142.7m USD
EBITDA TTM = 207.7m USD
Long Term Debt = unknown (none)
Short Term Debt = 5.35m USD (from shortTermDebt, last fiscal year)
Debt = 6.01m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -201.7m USD (from netDebt column, last quarter)
Enterprise Value = 5.02b USD (5.22b + Debt 6.01m - CCE 201.7m)
Interest Coverage Ratio = -3.28 (Ebit TTM 142.7m / Interest Expense TTM -43.5m)
FCF Yield = 3.31% (FCF TTM 166.3m / Enterprise Value 5.02b)
FCF Margin = 18.45% (FCF TTM 166.3m / Revenue TTM 901.1m)
Net Margin = 15.40% (Net Income TTM 138.8m / Revenue TTM 901.1m)
Gross Margin = 41.26% ((Revenue TTM 901.1m - Cost of Revenue TTM 529.3m) / Revenue TTM)
Gross Margin QoQ = 40.67% (prev 41.08%)
Tobins Q-Ratio = 5.13 (Enterprise Value 5.02b / Total Assets 978.3m)
Interest Expense / Debt = 3.41% (Interest Expense 205.0k / Debt 6.01m)
Taxrate = 26.06% (12.4m / 47.4m)
NOPAT = 105.5m (EBIT 142.7m * (1 - 26.06%))
Current Ratio = 3.22 (Total Current Assets 494.6m / Total Current Liabilities 153.4m)
Debt / Equity = 0.01 (Debt 6.01m / totalStockholderEquity, last quarter 702.5m)
Debt / EBITDA = -0.97 (Net Debt -201.7m / EBITDA 207.7m)
Debt / FCF = -1.21 (Net Debt -201.7m / FCF TTM 166.3m)
Total Stockholder Equity = 657.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.19% (Net Income 138.8m / Total Assets 978.3m)
RoE = 21.12% (Net Income TTM 138.8m / Total Stockholder Equity 657.0m)
RoCE = 17.29% (EBIT 142.7m / Capital Employed (Total Assets 978.3m - Current Liab 153.4m))
RoIC = 16.05% (NOPAT 105.5m / Invested Capital 657.0m)
WACC = 9.34% (E(5.22b)/V(5.22b) * Re(9.35%) + D(6.01m)/V(5.22b) * Rd(3.41%) * (1-Tc(0.26)))
Discount Rate = 9.35% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 0.19%
[DCF Debug] Terminal Value 77.31% ; FCFE base≈152.1m ; Y1≈187.6m ; Y5≈320.1m
Fair Price DCF = 145.7 (DCF Value 4.29b / Shares Outstanding 29.5m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 30.74 | EPS CAGR: -39.78% | SUE: -4.0 | # QB: 0
Revenue Correlation: 97.93 | Revenue CAGR: 15.84% | SUE: 0.59 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.31 | Chg30d=-0.019 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=5.43 | Chg30d=-0.002 | Revisions Net=-2 | Growth EPS=+12.8% | Growth Revenue=+8.3%
Additional Sources for BMI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle